Jeffrey V Poulton - 27 Feb 2024 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Signature
By: Stephen Hall, Attorney-in-Fact For: Jeffrey V. Poulton
Issuer symbol
ALNY
Transactions as of
27 Feb 2024
Net transactions value
-$89,145
Form type
4
Filing time
29 Feb 2024, 16:18:30 UTC
Previous filing
20 Feb 2024
Next filing
05 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Options Exercise $0 +1,908 +11% $0.000000 20,052 27 Feb 2024 Direct
transaction ALNY Common Stock Sale $38,171 -247 -1.2% $154.54 19,805 28 Feb 2024 Direct F1, F2
transaction ALNY Common Stock Sale $30,157 -194 -0.98% $155.45 19,611 28 Feb 2024 Direct F1, F3
transaction ALNY Common Stock Sale $17,984 -115 -0.59% $156.38 19,496 28 Feb 2024 Direct F1, F4
transaction ALNY Common Stock Sale $2,674 -17 -0.09% $157.30 19,479 28 Feb 2024 Direct F1, F5
transaction ALNY Common Stock Sale $158 -1 -0.01% $158.09 19,478 28 Feb 2024 Direct F1
holding ALNY Common Stock 57 27 Feb 2024 by Managed Account F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Restricted Stock Units Options Exercise $0 -1,908 -33% $0.000000 3,816 27 Feb 2024 Common Stock 1,908 Direct F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
F2 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
F7 Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
F8 On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.